Amyloid imaging shows promise for detecting cardiac amyloidosis

Feb. 4, 2013 ? While amyloid imaging may now be most associated with detecting plaques in the brain, it has the potential to change the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) with ¹¹C-PIB can positively visualize amyloid deposits in the heart. Currently there is no noninvasive test available for specific diagnosis.

Cardiac amyloidosis is a deadly disorder caused by abnormal amyloid deposits in the heart tissue. Early diagnosis before structural change to the heart tissue has occurred is important for disease prognosis and for treatment monitoring. Currently echocardiography is the mainstay of imaging in cardiac amyloidosis; a cardiac biopsy is used to confirm diagnosis.

"Imaging with ¹¹C-PIB provides a non-invasive and specific means of showing distribution of amyloid in an organ. This gives a unique opportunity to follow and monitor therapy, as amyloid deposits in the heart should decrease with successful therapy," said Gunnar Antoni, PhD, lead author of the study "In Vivo Visualization of Amyloid Deposits in the Heart with ¹¹C-PIB and PET."

The study included 10 patients diagnosed with cardiac amyloidosis and five healthy individuals. PET/computed tomography (CT) with ¹¹C-PIB was used to visualize amyloid deposits in the heart and with ¹¹C-acetate to measure myocardial blood flow.

Uptake of ¹¹C-PIB was measured 15-25 minutes after injection. Obvious uptake of ¹¹C-PIB was noted in the left ventricle wall of all patients with cardiac amyloidosis, while no uptake was seen in the healthy volunteers. In half of the patients, ¹¹C-PIB was also detected in the right ventricle wall, and nine of the patients had signs of reversible uptake, with a maximum concentration at 10-15 minutes after injection. Myocardial blood flow was significantly lower in patients with cardiac amyloidosis; however, no significant correlation between myocardial blood flow and ¹¹C-PIB uptake was found.

"This study emphasizes the strength of molecular imaging for detecting an underlying and significant molecular aberration in a disease that presents with unspecific symptoms and signs," noted Antoni. "The potential for molecular imaging to provide valuable information for other diseases is of great value to the field of medicine."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by Society of Nuclear Medicine.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Journal Reference:

1. G. Antoni, M. Lubberink, S. Estrada, J. Axelsson, K. Carlson, L. Lindsjo, T. Kero, B. Langstrom, S.-O. Granstam, S. Rosengren, O. Vedin, C. Wassberg, G. Wikstrom, P. Westermark, J. Sorensen. In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET. Journal of Nuclear Medicine, 2012; 54 (2): 213 DOI: 10.2967/jnumed.111.102053

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/top_health/~3/jOIv5AOvRg8/130204114252.htm

amare stoudemire tallest building in the world the pitch brandon inge freedom tower freedom tower eric church